Apogem Capital LLC Cue Biopharma, Inc. Transaction History

Apogem Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.23 - $3.37 $27,950 - $42,239	-12,534 Reduced 10.18%	110,614 $247,000
Q2 2022 Aug 15, 2022	BUY	$2.49 - $5.92 $29,603 - $70,382	11,889 Added 10.69%	123,148 $307,000
Q1 2022 May 16, 2022	BUY	$4.41 - $12.28 $215,931 - $601,277	48,964 Added 78.6%	111,259 $543,000
Q4 2021 Feb 14, 2022	BUY	$10.86 - $17.85 $114,344 - $187,942	10,529 Added 20.34%	62,295 $705,000
Q3 2021 Nov 15, 2021	BUY	$10.06 - $15.3 $38,358 - $58,338	3,813 Added 7.95%	51,766 $754,000
Q2 2021 Aug 16, 2021	BUY	$10.9 - $14.53 $57,235 - $76,297	5,251 Added 12.3%	47,953 $559,000
Q1 2021 May 14, 2021	SELL	$11.2 - $16.09 $149,329 - $214,527	-13,333 Reduced 23.79%	42,702 $521,000
Q4 2020 Feb 16, 2021	BUY	$11.12 - $16.4 $623,109 - $918,973	56,035 New	56,035 $701,000

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Apogem Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Apogem Capital LLC with notifications on news.